Abstract
The outbreak of Covid-19 infection has become a pandemic affecting millions of people throughout the world. No specific antiviral drugs have been approved for the treatment of Covid-19. The antiretroviral drug favipiravir (FAV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. China’s Science and Technology Ministry official announced that Japan-based anti-flu drug FAV has been observed to help Covid-19 patients recover.
Highlights
The novel human coronavirus disease, Covid-19 which was first reported in Wuhan, China, in December 2019 has spread around the world affecting millions of people
The study is approved by a local ethics committee, written informed consents were obtained from all participants
An LC-MS/MS method using protein precipitation with an lower limit of quantitation (LLOQ) of 80 ng/mL was developed for the determination of FAV in human plasma
Summary
The novel human coronavirus disease, Covid-19 which was first reported in Wuhan, China, in December 2019 has spread around the world affecting millions of people. An official from the Science and Technology Ministry in China, stated that Favipiravir (FAV) was clearly effective in the treatment of Covid-19 and has been experimentally used for Covid-19 treatment. The aim of the study was to develop and validate a simple, cost effective and sensitive LCMS/MS method for the determination of FAV in human plasma to be utilized in bioequivalence studies. Different quantitative methods have been described in the literature for analysis of favipiravir in human serum [10]. There are no Citation: Saraner N, Guney B, Sevici G, Saglam O (2021) Determination of Favipiravir in Human Plasma by Using Liquid ChromatographyTandem Mass Spectrometry: Application to Pharmacokinetic Studies.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
